Overview

A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
0
Participant gender:
All
Summary
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Otsuka America Pharmaceutical
Treatments:
Antidepressive Agents
Aripiprazole
Criteria
Inclusion Criteria:

- Men and women, 18-65 years old

- Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks
in duration.

- Treatment history of an inadequate response to at least one and no more than three
antidepressants.